Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients
Open Access
- 1 October 2015
- journal article
- Published by Springer Nature in Saudi Pharmaceutical Journal
- Vol. 23 (5) , 544-548
Abstract
The efficacy of human recombinant erythropoietins (rHuEPOs) in the treatment of anemia with different etiologies is proven. Development of biosimilar rHuEPO products with lower cost and wider availability is important for the care of anemic patients. The aim of the present study was to determine the bioequivalence and safety of a biosimilar rHuEPO (Pastopoitin(®)) and compare it with the innovator product Eprex(®), as a standard rHuEPO. One hundred and seven anemic patients on stable hemodialysis were recruited to this randomized double-blind comparative trial and assigned to either subcutaneous Pastopoitin (n = 50) or Eprex (n = 57). Each study group received rHuEPO at a dose of 80-120 IU/kg/week in 2-3 divided doses for a period of 3 months. Hematologic parameters including Hemoglobin, hematocrit, RBC, EBC, platelet, MCV, MCH and MCHC were checked every 2 weeks. Blood iron, ferritin, TIBC, creatinine, BUN and electrolytes (Na, K, Ca and P) were evaluated monthly over the 3 months. A significant increase in hemoglobin, hematocrit and RBC was observed by the end of study in both Pastopoitin and Eprex groups (p < 0.001). However, these factors were not significantly different between the groups, neither at baseline nor at the end of study (p > 0.05). Likewise, the groups were comparable regarding MCV, MCH, MCHC, iron, ferritin, TIBC, creatinine, BUN and electrolytes at baseline as well as at the end of trial. Adverse events were not serious and occurred with the same frequency in the study groups. Pastopoitin showed comparable efficacy and safety profile with Eprex in anemic patients on hemodialysis. Hence, Pastopoitin may be considered as a rHuEPO with a lower cost and wider availability compared with the innovator product Eprex.Keywords
Funding Information
- Clinical Trial Research Center, Tehran, Iran
This publication has 21 references indexed in Scilit:
- Erythropoietin Safety and Efficacy in Chronic Allograft NephropathyTransplantation Proceedings, 2007
- Recombinant Human Erythropoietin for the Treatment of Anaemia in Patients with Chronic Idiopathic MyelofibrosisActa Haematologica, 2006
- Anemia in chronic kidney disease: causes, diagnosis, treatment.Cleveland Clinic Journal of Medicine, 2006
- The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin β in peritoneal dialysis patients with chronic renal anaemiaNephrology Dialysis Transplantation, 2005
- Cost-Effectiveness of Recombinant Human Erythropoietin for Reducing Red Blood Cells Transfusions in Critically Ill PatientsValue in Health, 2005
- The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: results from a randomized controlled multicentre trialNephrology Dialysis Transplantation, 2000
- Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobinAmerican Journal of Kidney Diseases, 1999
- Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective studyNephrology Dialysis Transplantation, 1996
- Serum Erythropoietin Levels in the Immediate Kidney-Posttransplant PeriodNephron, 1992
- Analysis of the Quantitative Relationship Between Anemia and Chronic Renal FailureThe American Journal of the Medical Sciences, 1989